COVAX No-Fault Compensation Program for Advance Market Commitment (AMC) Eligible Economies is the world’s first and only international vaccine injury compensation mechanism. The Program helps COVAX deliver safe and effective COVID-19 vaccines to the high-risk and vulnerable populations in 92 low- and middle-income countries and economies. It provides fair, no-fault, lump sum compensation to eligible individuals who suffer certain serious adverse events after receiving a COVID-19 vaccine distributed through the COVAX Facility until 30 June 2022.
There has been no compromise on safety in the development of the COVID-19 vaccines delivered through COVAX, and serious adverse events are rare. The benefits of COVID-19 vaccines in reducing severe health consequences and deaths from COVID-19 disease, far outweigh the risks of serious adverse events. But if serious adverse events occur, eligible individuals can seek compensation through a robust, transparent and fast application process.
In addition to providing fair compensation to eligible individuals, COVAX No-Fault Compensation Program aims to decrease potential financial burdens on the governments of the above mentioned 92 low- and middle-income countries and economies. It is funded by a small levy on each dose distributed through COVAX to these countries and economies. No fee is charged to apply for compensation under the Program.
COVAX No-Fault Compensation Program ensures that people in Advance Market Commitment eligible economies can benefit from the cutting-edge science that has delivered COVID-19 vaccines in record time.
Entire content available on: https://www.who.int/initiatives/act-accelerator/covax/no-fault-compensation
